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Abstract: Numerous inflammatory and innate immune pathways are involved in atherogenesis. Elaboration of clinical 
models of inflammation-induced atherogenesis may further advance our knowledge of multiple inflammatory pathways 
implicated in atherogenesis and provide a useful tool for cardiovascular prevention. Familial Mediterranean fever (FMF) 
is a chronic inflammatory disorder with profiles of inflammatory markers close to that seen in the general population. In a 
few recent studies, it has been shown that endothelial dysfunction, increased atherosclerotic burden and activation of 
platelets accompany attack-free periods of FMF. Colchicine is proved to be useful in suppression of inflammation in 
FMF.  Preliminary  basic  and  clinical  studies  suggest  that  this  relatively  safe  drug  may  be  useful  for  cardiovascular  
protection in patients with FMF and in the general population. Multinational prospective studies are warranted to further 
elaborate clinical model of inflammation-induced atherosclerosis associated with FMF.  
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INTRODUCTION 
  Atherosclerosis  is  the  main  contributor  to  the  global 
morbidity and mortality [1]. It starts early in life, progresses 
slowly and asymptomatically with aging, eventually result-
ing in atherosclerotic cardiovascular disease, adverse vascu-
lar events and death. Staggering amount of evidence derived 
from experimental and clinical studies suggests that multiple 
immune and inflammatory agents orchestrate atherosclerotic 
vasculopathy throughout the whole course of atherogenesis 
[2,3]. 
  Initial stages of atherosclerotic vasculopathy are charac-
terized by disruption of the integrity of endothelial mono-
layer, exposure of the constituents of subendothelial space to 
the  blood  flow,  recruitment  of  immune  and  inflammatory 
cells into the vascular wall, vascular inflammation and dec- 
reased production of vasoprotective agents [4, 5]. An interac-
tion of endothelial cells with T- and B-lymphocytes, neut- 
rophils, platelets and numerous  immune  and inflammatory 
agents produced by these cells leads toward atherosclerotic 
plaque formation, its destabilization and rupture [6-9]. 
  Over  the  past  decade,  it  has  become  evident  that  up-
regulation  of  inflammation  and  autoimmune  aggression  in 
certain systemic disorders such as systemic lupus erythema-
tosus (SLE) and rheumatoid arthritis (RA) may substantially 
accelerate  atherogenesis  and  increase  the  risk  of  vascular 
events  [10-12].  Basic  and  clinical  research  studies  in  this 
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field  have  led  to  the  emergence  of  a  new  biomedical  
discipline, vascular rheumatology [13], which aims to clarify 
pathophysiology  of  rheumatic  diseases  and  co-morbidities 
and to propose recommendations for primary and secondary 
prevention  of  vascular  events  in  the  general  population. 
Clinical  models  of  inflammation-induced  atherosclerosis 
elaborated  over  the  past  decade  are  mainly  based  on  the  
cardiovascular phenomenon described within the frames of 
high-grade inflammatory conditions. Much less attention has 
been paid to atherogenesis in low-grade inflammatory condi-
tions, such as psoriatic arthritis [14, 15], ankylosing spondy-
litis [16] and familial  Mediterranean fever (FMF) [17, 18] 
which manifest with inflammatory profiles close to that seen 
in  the  general  population.  Better  understanding  of  diverse 
inflammatory  pathways  associated  with  atherogenesis  may 
provide useful tools for cardiovascular prevention with drugs 
proved  their  efficiency  in  these  disorders  (for  example,  
colchicine in FMF).  
  The aim of the current mini-review  is to discuss latest 
data supporting the concept of FMF as a clinical model of 
atherogenesis associated with low-grade inflammation. 
FMF  AS  A  LOW-GRADE  INFLAMMATORY  
DISORDER 
  FMF has been classified as a systemic autoinflammatory 
disorder characterized by seemingly unprovoked activation 
of diverse inflammatory pathways [19, 20]. It is an ancient 
disease with wide-spread distribution in the Eastern Mediter-
ranean region and sporadic occurrence throughout the world. 
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However, it is largely recognized as an autosomal recessive 
trait  associated with  missense mutations in  the  MEditerra-
nean FeVer (MEFV) gene located on the short arm of chro-
mosome  16  [21].  The  gene  is  predominantly  expressed  in 
neutrophils [22]. The mutant pyrin protein encoded by the 
MEFV gene contains 781 amino acids and 4 domains (pyrin 
N-terminal, B-BOX type zinc finger, Coiled Coil and B30.2 
C-terminal).  The  B30.2  domain  encoded  by  the  last,  10
th 
exon of the MEFV gene which is the location of all severe 
mutations (M694V,  M694I,  M680I) [21].  These  mutations 
are responsible for dysregulation of apoptosis and inflamma-
tion due to the reduced ability of the mutated pyrin protein to 
modulate  activity  of  inflammasome  and  interleukin-1beta 
(IL-1beta)  [19].  Importantly,  the  same  mutations  were  
found responsible for subclinical inflammation in apparently 
healthy subjects [23, 24] and were associated with myocar-
dial  infarction  (MI)  in  the  general  population  [25],  severe  
course of inflammation with arthritis in inflammatory bowel 
disease [26], vascular involvement in Behçet’s disease (BD) 
[27]. 
  The hallmark of FMF is a self-limiting febrile attack of 
polyserositis followed by attack-free period. In a large pro-
portion of patients symptom-free intervals of the disease are 
characterized by subclinical inflammation with overproduc-
tion of C-reactive protein (CRP), serum amyloid A (SAA) 
and other acute-phase reactants [28,29]. During attack-free 
periods,  patients  with  FMF  may  still  experience  arthritis, 
myalgia, autonomic dysregulation with altered cardiovascu-
lar reactivity [30] and other cardiovascular symptoms related 
to  persistent  subclinical  inflammation  [18].  Importantly,  
recent  studies  with  cardiovascular  imaging  techniques  
identified signs of diastolic dysfunction  and microvascular 
coronary  pathology  which  were  correlated  with  elevated 
levels  of  CRP  during  attack-free  period  [31,  32].  Clinical 
significance  of  coronary  pathology  in  FMF  was  also  
highlighted in a few previous reports of coronary vasculitis, 
transient  left  bundle  branch  block  and  MI  associated  with 
inflammation in FMF [33-35].  
  Persistent  inflammation  in  FMF  may  cause  endothelial 
dysfunction, atherothrombosis and systemic amyloidosis, all 
of which share some genetic,  immunological  and morpho-
logical  features  [36].  Systemic  amyloidosis  is  the  most 
dreadful  manifestation  of  the  disease  which  define  its  
outcome [37, 38].  Rarely, amyloidosis  in  FMF  affects the 
myocardium and coronary vessels [39-41].  
ENDOTHELIAL DYSFUNCTION IN FMF 
  Endothelial cells play a crucial role in the migration of 
activated  neutrophils  into  the  subendothelial  space  and  in  
the initiation of the vessel wall inflammation [42]. Endothe-
lial  adhesion  molecules,  such  as  intercellular  adhesion  
molecule-1 (ICAM-1) and vascular cell adhesion molecule-1 
(VCAM-1),  facilitate  cellular  interactions  between  neutro-
phils,  T-  and  B-lymphocytes,  monocytes/macrophages,  
endothelial cells, whereas neutrophils, as an abundant source 
of  oxygen  reactive  species  and  proteolytic  enzymes,  act 
against endothelial cell junctions, thus opening route toward 
vascular smooth muscle cell [43]. This basic mechanism of 
endothelial  dysfunction  initiated  by  neutrophils  underlies 
diverse disorders associated with inflammation [44, 45] and 
may play even more active role in FMF. 
  Though vasculopathic cellular and molecular agents are 
not fully explored within the frames of FMF, neutrophils are 
believed  to  be  the  main  inflammatory  cells  implicated  in 
endothelial dysfunction, oxidative stress and overproduction 
of adhesion molecules in this disorder [46]. Neutrophils of 
patients  with  FMF  may  remain  hyperactive  during  attack-
free period due to the sustained overproduction of interleu-
kins-17 (IL-17) and -18 (IL-18) [47]. Of note, IL-18 is one 
of  the  main  pro-inflammatory  cytokines,  exerting  its  pro-
atherogenic effects via inflammasome activation and release 
of adhesion molecules [48], secretion of interferon-gamma 
[49] and upregulation of other pro-inflammatory cytokines 
(e.g., interleukin-8 [IL-8]) [50]. 
  It  has  been  shown  that  attack-free  period  in  FMF  is  
characterized by ongoing endothelial damage with elevation 
of  circulating  markers  of  endothelial  dysfunction  such  as 
thrombomodulin  [51],  adrenomedullin  and  nitrite  [52].  
Elevated  CRP  [53]  and  vascular  endothelial  growth  factor 
[54,  55]  can  be  considered  as  direct  contributors  to  the  
vascular damage and endothelial dysfunction in FMF.  
PROTHROMBOTIC STATE IN FMF 
  Over the past few years, several reports have been pub-
lished, linking subclinical inflammation with markers of hy-
percoagulation and thrombosis in FMF [56-60]. As a result, 
it has become possible to formulate hypothesis which con-
siders FMF as a prothrombotic disorder [57]. Interestingly, 
implications of the MEFV gene in thrombosis have not been 
investigated in FMF, but its common mutations have been 
associated  with  the  susceptibility  to  venous  thrombosis  in 
BD [61]. 
  Hypercoagulation in attack-free period in FMF was charac- 
terized by shortened prothrombin time and  thrombin  time, 
decreased  protein  C  activity  and  elevation  of  prothrombin 
fragment F1+2 [56]. Besides, in one study, platelet activation 
was  documented  by  an  increase  of  the  size  of  circulating 
platelets during the same period in FMF [62]. However, in 
another  similar  study,  there  was  no  difference  in  platelet 
function  among  patients  with  FMF  and  healthy  controls 
which was interpreted as a positive (anti-platelet) effect of 
colchicine therapy [63].  
  It  should  be  emphasized  that  platelet  activation  is  an  
essential  link  between  inflammatory,  thrombotic  and  
atherogenic pathways [64]. Activated platelets interact with  
neutrophils  and  endothelial  cells  and  through  the  release  
of  P-selectin  and  other  pro-inflammatory  agents  facilitate  
participation of immune cells in vascular inflammation and 
atherogenesis [65]. 
  In this regard, further studies are warranted to investigate 
interaction of platelets with markers of inflammation derived 
from other cells (e.g., IL-8, neutrophilic enzymes, CRP) and 
to determine vascular predictive value of activated platelets 
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ATHEROSCLEROTIC BURDEN IN FMF 
  Surrogate markers of atherosclerosis, such as the carotid 
artery intima-media thickness (IMT) has emerged as an useful 
tool  for  assessment  of  the  burden  of  atherosclerosis  and  
efficiency of cardiovascular therapies [66]. In most studies, 
the observed association of circulating inflammatory markers 
with an increased carotid artery IMT in chronic inflammatory 
disorders led to a conclusion that these disorders are associ-
ated with accelerated atherosclerosis and heightened risk of 
atherothrombotic events [67]. 
  Atherosclerotic  burden  measured  by  the  carotid  artery 
IMT  was  also  assessed  in  patients  with  FMF  [17,  68-71]. 
Intima-media  thickening  was  associated  with  elevation  of 
SAA and fibrinogen during attack-free period [17]. None of 
the  studies  investigating  carotid  atherosclerosis  in  FMF 
found  an  increase  of  the  prevalence  of  atherosclerotic 
plaques which was seen in high-grade inflammatory disor-
ders (e.g., SLE, RA). The latter can be interpreted as a result 
of less aggressive course of atherosclerosis in FMF [71]. It 
is, however, possible to speculate that colchicine therapy was 
responsible for less aggressive course of atherogenesis in the 
most studies in FMF. Prospective studies with the patients 
examined  for  atherosclerotic  burden  at  baseline  (when  the 
diagnosis is made and colchicine administered) and at sev-
eral time-points of the long-term follow-up, most probably, 
will  ascertain  whether  colchicine  affects  the  course  of 
atherogenesis in FMF.  
COLCHICINE THERAPY AND ATHEROGENESIS 
  Colchicine  is  an  alkaloid  derived  from  the  plant  Col-
chicum autumnale. Extract of the plant has been successfully 
used for the treatment of gouty arthritis for centuries [72]. 
Also,  colchicine  has  been  demonstrated  effectiveness  in 
various inflammatory and (auto)immune disorders (e.g., liver 
cirrhosis, necrotizing vasculitis, BD, psoriasis, scleroderma, 
sarcoidosis,  thrombocytopenic  purpura,  pericarditis,  skin 
diseases with neutrophils infiltration) [72, 73]. However, the 
first report on successful treatment of attacks of FMF with 
colchicine  published  in  1972  [74]  and  large  clinical  trials 
[75, 76] distinguished colchicine as a drug of choice for pre-
vention  of  attacks  and  amyloidosis  in  FMF.  As  a  result, 
nowadays, regular colchicine intake at a dose of 1-2 mg/day 
is  considered as a relatively safe and  effective therapeutic 
option for the suppression of inflammation and prevention of 
inflammatory co-morbidities in FMF [77].  
  The  main  mechanism  of  action  of  colchicine,  favoring  
its use in FMF, is dependent on selective  accumulation in 
neutrophils,  disruption  of  polymerization  of  microtubules, 
and suppression of neutrophils chemotaxis [78]. Colchicine 
alters expression of the MEFV [79] and other genes regulat-
ing  inflammatory  pathways  [80]  exerts  anti-cytokinergic  
and fibrolytic  effects [81, 82] further expanding its use  in  
inflammatory disorders (most notably in recurrent pericardi-
tis [83]). 
  Preliminary  data  suggest  that  anti-inflammatory  profile 
of colchicine may have cardiovascular implications in FMF. 
In a 6-month colchicine trial, patients with FMF at preamy-
loidal  and  early  amyloidal  stages  demonstrated  significant 
improvement of diastolic function [84]. In another retrospec-
tive study with a large cohort of FMF patients (n=290) regu-
larly treated with colchicine the prevalence of ischemic heart 
disease  (IHD)  and  established  cardiovascular  risk  factors 
were comparable to that of healthy controls [85]. 
  Promising results of the studies on anti-inflammatory and 
cardioprotective effects of colchicine in FMF made it possi-
ble to investigate benefits of colchicine in patients with car-
diovascular  disease  with  elevated  levels  of  inflammatory 
markers. In particular, in a one-month study with 44 patients 
with stable IHD and elevated CRP (>2.0 mg/L), colchicine 
(1 mg/day) significantly lowered CRP without side effects 
[86]. Unfortunately, owing to the safety concerns, there are 
no  long-term  studies  which  could  clarify  whether  the  ob-
served effect on CRP has implications in terms of reducing 
vascular events. 
  Established  short-term  anti-inflammatory  effects  and 
safety profile of colchicine may however have implications 
for prevention of restenosis in patients undergoing percuta-
neous transluminal angioplasty. Although clinical evidence 
to support this hypothesis is non-existent (perhaps due to the 
safety  concerns),  one  recent  experimental  study  on  an-
gioplasty of iliofemoral arteries in dogs demonstrated safety 
and  dose-dependent  potential  of  colchicine  in  preventing 
intimal hyperplasia within 2 weeks of the drug therapy [87]. 
Importantly,  further  studies  in  different  animal  models  of 
angioplasty at coronary and other vascular sites with differ-
ent regimes of colchicine therapy (oral intake, local applica-
tion,  low,  moderate,  high  doses)  are  warranted  before  
clinical studies. 
CONCLUSIONS 
  Preliminary  studies  suggest  that  attack-free  periods  of 
FMF  are  characterized  by  subclinical  inflammation  and  
associated endothelial dysfunction, increased atherosclerotic 
burden  and  platelets  activation.  Colchicine  demonstrated 
relatively  safe  anti-inflammatory  potential  which  seems  
potentially  useful  for  amelioration  of  endothelial  function, 
suppression  of  prothrombotic  pathways  and  decrease  of  
atherosclerotic  burden  (Fig.  1).  The  effects  of  colchicine  
on  cardiovascular  morbidity  and  mortality  have  not  been 
studied  prospectively.  Nevertheless,  clinical  experience  on 
regular colchicine therapy accumulated over the past decades 
suggests that in populations of patients exposed to colchicine 
from  early  stages  of  the  disease  (e.g.,  the  patients  from  
Israel)  the  prevalence  of  IHD  is  not  higher  than  that  in  
the general population [85]. Moreover, in most previous ret-
rospective studies, those on regular colchicine therapy were 
free  of  established  cardiovascular  risk  factors,  such  as 
dyslipidemia  and  hypertension.  Given  the  differences  in 
clinical  manifestations,  cardiovascular  risk  profiles  and  
responsiveness to colchicine in populations of FMF patients 
from  different  countries,  multinational  prospective  studies 
with  emphasis  on  established  and  novel  risk  factors  and  
vascular events in FMF are recommended.  
  New  opportunities  for  targeted  use  of  cardiovascular  
and  disease-modifying  drugs  in  FMF  and  other  low-grade 54    The Open Cardiovascular Medicine Journal, 2010, Volume 4  Yüksel et al. 
inflammatory disorders may emerge with future prospective 
studies specifically looking at cardiovascular risk profiles in 
association with several inflammatory (IL-1beta, IL-6, IL-8, 
TNF-alpha,  IL-18)  and  genetic  markers  (the  MEFV  gene 
mutations).  
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